Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Prognostic value of kappa free light chain index in patients with primary progressive multiple sclerosis
Avtorji:ID Schmidauer, Martin (Avtor)
ID Berek, Klaus (Avtor)
ID Auer, Michael (Avtor)
ID Bsteh, Gabriel (Avtor)
ID Cavalla, Paola (Avtor)
ID Di Pauli, Franziska (Avtor)
ID Di Filippo, Massimiliano (Avtor)
ID Deisenhammer, Florian (Avtor)
ID Emeršič, Andreja (Avtor)
ID Rot, Uroš (Avtor), et al.
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (584,58 KB)
MD5: E19F01993685E01B3AF09353E89ABD66
 
URL URL - Izvorni URL, za dostop obiščite https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1658182/full
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Background: The kappa free light chain (κ-FLC) index is a well-established biomarker in multiple sclerosis (MS). While the prognostic value of the κ-FLC index has been demonstrated in early relapsing-remitting MS, its prognostic value in primary progressive MS (PPMS) has not yet been investigated. Methods: In this multicenter, retrospective cohort study, patients diagnosed with PPMS with diagnostic lumbar puncture and clinical follow-up of at least 12 months were recruited from nine MS centers across five countries. At baseline, age, sex, disease duration, and the number of T2 hyperintense (T2L) and contrast-enhancing T1 lesions (CEL) on MRI were determined. κ-FLC was measured using nephelometry/turbidimetry, and the κ-FLC index was calculated as (CSF κ-FLC/serum κ-FLC)/albumin quotient. At follow-up, the occurrence of disability progression and the administration of disease-modifying treatment (DMT) were registered. The primary endpoint was time to disability progression. Results: A total of 121 PPMS patients were included with a median age of 53 years (25th-75th percentile: 46-59) and a balanced sex distribution (48.8% female). Multivariable Cox regression analysis revealed no significant association between the κ-FLC index and disability progression [hazard ratio (HR) 1.0, p = 0.950]. Prior use of DMT (HR 0.60, p = 0.023) and brain T2L > 9 at baseline (HR 2.22, p = 0.026) were significantly associated with disability progression. The remaining covariates, including age, sex, disease duration, and CEL, showed no significant associations. Conclusion: The κ-FLC index does not predict disability progression in PPMS, contrasting its growing role as a prognostic biomarker in relapsing MS. This highlights phenotypic differences in MS pathophysiology and underscores the need for prognostic biomarkers in PPMS.
Ključne besede:cerebrospinal fluid, kappa free light chain, multiple sclerosis, primary progressive, prognostic biomarker
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:str. 1-9
Številčenje:Vol. 16, [article no.] 1658182
PID:20.500.12556/DiRROS-25346 Novo okno
UDK:616.8
ISSN pri članku:1664-3224
DOI:10.3389/fimmu.2025.1658182 Novo okno
COBISS.SI-ID:264776451 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 15. 1. 2026;
Datum objave v DiRROS:16.01.2026
Število ogledov:293
Število prenosov:219
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Frontiers in immunology
Skrajšan naslov:Front. immunol.
Založnik:Frontiers Research Foundation
ISSN:1664-3224
COBISS.SI-ID:30774233 Novo okno

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:cerebrospinalna tekočina, prosta kappa lahka veriga, multipla skleroza, primarna progresivna skleroza, prognostični biomarker


Nazaj